Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05439278

Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients

Sponsor: Severance Hospital

Conditions Glioblastoma

Interventions Conventional radiotherapy Hypofractionated radiotherapy Temozolomide

Updated 5 times since 2022 Last updated: May 15, 2025 Started: Feb 1, 2025 Primary completion: Dec 31, 2028 Completion: Dec 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05439278, this PHASE3 trial focuses on Glioblastoma and remains actively recruiting participants. Sponsored by Severance Hospital, it has been updated 5 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Jun 2025 [monthly]

Not Yet Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE3
Jul 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Severance Hospital

Data source: Severance Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea